Charles M Watts
CIK 1723751 · last filed 2025-04-02
Charles M Watts is a corporate insider who has filed 22 SEC Form 4 insider transactions across 2 companies since 2017. The most recent filing, for BDSX, was dated Apr 2, 2025. Across all open-market trades the lifetime net is +$111.1K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $218.0K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BDSX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
TUCSON, AZ 85714
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BDSX | Director | 21,085 | $10.34 | $218.0K | $111.1K | 15 | 2025-04-02 |
| Accelerate Diagnostics, Inc (AXDX) Delisted | Director | 6,962 | $0.03 | $237 | $0 | 7 | 2023-05-26 |
Recent Filings
22 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-04-02 | BDSX | Exer (M) | +46,686 | $0 | EDGAR |
| 2024-07-18 | BDSX | Exer (M) | +26,368 | $0 | EDGAR |
| 2024-05-23 | BDSX | Grant (A) | — | $0 | EDGAR |
| 2024-04-03 | BDSX | Exer (M) | +134,262 | $0 | EDGAR |
| 2024-01-03 | BDSX | Grant (A) | — | $0 | EDGAR |
| 2023-08-07 | BDSX | Grant (A) | +12,345 | $20.0K | EDGAR |
| 2023-05-26 | Accelerate Diagnostics, Inc (AXDX) Delisted | Exer (M) | +69,619 | $0 | EDGAR |
| 2023-05-25 | BDSX | Grant (A) | — | $0 | EDGAR |
| 2023-04-04 | BDSX | Exer (M) | +150,711 | $0 | EDGAR |
| 2023-01-05 | BDSX | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.